Expression data from mouse endothelial cell in human ovarian cancer

To examine potential mechanisms underlying resistance to anti-VEGF antibody (AVA) therapy, we used mouse models to identify tumors that demonstrated growth subsequent to a period of initial response. Specifically, we established orthotopic mouse models of ovarian cancer designed to develop adaptive resistance after treatment with an AVA. To examine potential mechanisms underlying resistance to anti-VEGF antibody (AVA) therapy, we used mouse models to identify tumors that demonstrated growth subsequent to a period of initial response. Specifically, we established orthotopic mouse models of ovarian cancer designed to develop adaptive resistance after treatment with an AVA. We extracted total RNA from B20-sensitive and B20-resistant tumor endothelial cells with use of an RNeasy mini kit (Qiagen). A NanoDrop spectrophotometer (Thermo Fisher Scientific) was used for assessment of both RNA quality and quantity. Total RNA (700 ng) was labeled and hybridized to Bead Chips according to the manufacturer’s protocols